|
|
肺腺鳞癌的临床特征、分子特征及预后
|
Abstract:
肺腺鳞癌是由腺癌和鳞癌两种混合成分构成的一种比较罕见的肺癌类型，它的发病率比较低，仅占肺癌的0.4%~4%，肺腺鳞癌具有与肺腺癌和肺鳞癌相似的生物学特征，但其早期发现和诊断比较困难，容易侵袭周围组织和远处转移，预后也不理想。目前，随着基因检测技术的逐渐成熟，以EGFR-TKIs为代表的靶向治疗和以PD-L1免疫检查点抑制剂为代表的免疫治疗临床应用显著延长了肺腺鳞癌患者的生存时间。对肺腺鳞癌特征的深入研究，有助于为临床诊疗提供更多的方法和思路，实施精准化治疗，更好地改善患者的预后。
Adenosquamous carcinoma of lung is a rare type of lung cancer composed of adenocarcinoma and squamous cell carcinoma. Its incidence is relatively low, accounting for only 0.4% to 4% of lung cancer. However, adenosquamous cell carcinoma of lung has similar biological characteristics to those of adenocarcinoma and squamous cell carcinoma of lung, but its early detection and diagnosis are difficult, easy to invade surrounding tissues and distant metastasis, and its prognosis is not ide-al. At present, with the gradual maturation of gene detection technology, the clinical application of targeted therapy represented by EGFR-TKIs and immunotherapy represented by PD-L1 immune checkpoint inhibitors has significantly prolonged the survival time of lung adenosquamous cell car-cinoma patients. In-depth study on the characteristics of lung adenosquamous cell carcinoma is helpful to provide more methods and ideas for clinical diagnosis and treatment, implement precise treatment, and better improve the prognosis of patients.
| [1] | 毕向雁, 李和根, 马恰怡, 孙建立, 周蕾, 朱立峰, 蔡浦玉, 谭翔文. 一例肺腺鳞癌TKI治疗后病理转化报道[J]. 实用肿瘤杂志, 2021, 36(6): 571-574. |
| [2] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A. and Bray, F. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [3] | Liang, J., Sui, Q., Zheng, Y., Bi, G., Chen, Z., Li, M., Huang, Y., Lu, T., Zhan, C. and Guo, W. (2020) A Nomogram to Predict Prognosis of Patients with Lung Adenosquamous Carcinoma: A Population-Based Study. Journal of Thoracic Disease, 12, 2288-2303. https://doi.org/10.21037/jtd.2020.03.115 |
| [4] | Wang, J., Wang, Y., Tong, M., Pan, H. and Li, D. (2018) Research Progress of the Clinicopathologic Features of Lung Adenosquamous Carcinoma. OncoTargets and therapy, 11, 7011-7017. https://doi.org/10.2147/OTT.S179904 |
| [5] | Li, Y., Wu, X., Huang, Y., Bian, D. and Jiang, L. (2020) 18F-FDG PET/CT in Lung Adenosquamous Carcinoma and Its Correlation with Clinicopathological Features and Prog-nosis. Annals of Nuclear Medicine, 34, 314-321.
https://doi.org/10.1007/s12149-020-01450-1 |
| [6] | 赵文君, 王旭, 马克威. 肺腺鳞癌研究进展[J]. 中华肿瘤杂志, 2017, 39(4): 241-244. |
| [7] | Zhu, L., Jiang, L., Yang, J., Gu, W. and He, J. (2018) Clinical Characteristics and Prog-nosis of Patients with Lung Adenosquamous Carcinoma after Surgical Resection: Results from two Institutes. Journal of Thoracic Disease, 10, 2397-2402. https://doi.org/10.21037/jtd.2018.03.186 |
| [8] | 周生余, 薛奇, 应建明, 胡兴胜, 杨建良, 林华, 石远凯. 肺腺鳞癌的临床病理和分子生物学特征及其预后影响因素分析[J]. 中华肿瘤杂志, 2019, 41(1): 50-55. |
| [9] | Pan, F., Cui, S., Wang, W., Gu, A. and Jiang, L. (2018) Survival Analysis for Lung Adenosquamous Carcinoma Patients with Brain Metastasis. Journal of Cancer, 9, 3707-3712. https://doi.org/10.7150/jca.27441 |
| [10] | Borczuk, A.C. (2018) Uncommon Types of Lung Carcinoma with Mixed Histology: Sarcomatoid Carcinoma, Adenosquamous Carcinoma, and Mucoepidermoid Carcinoma. Archives of Patholo-gy and Laboratory Medicine, 142, 914-921.
https://doi.org/10.5858/arpa.2017-0584-RA |
| [11] | 刘海波, 张诗杰. 肺腺鳞癌的临床现状及研究进展[J]. 中国综合临床, 2022, 38(4): 304-307. |
| [12] | Wu, X., Yu, W., Petersen, R.H., Sheng, H., Wang, Y., Lv, W. and Hu, J. (2020) A Competing Risk Nomogram Predicting Cause-Specific Mortality in Patients with Lung Adenosquamous Carcinoma. BioMed Central Cancer, 20, 429-439. https://doi.org/10.1186/s12885-020-06927-w |
| [13] | 谢玉华, 李升锦. 肺腺鳞癌治疗研究进展[J]. 世界最新医学信息文摘, 2020, 20(27): 136-137, 140. |
| [14] | Li, H., Wang, Z., Yang, F. and Wang, J. (2020) Development and Validation of a Nomogram for Predicting Cancer-Specific Survival of Surgical Re-sected Stage I-II Adenosquamous Carcinoma of the Lung. Journal of Surgical Oncology, 121, 1027-1035. https://doi.org/10.1002/jso.25858 |
| [15] | 吴杰, 吴忠纯, 肖辉, 闫鹏, 王石川. 13例肺腺鳞癌的CT图像分析[J]. 山东医药, 2017, 57(47): 93-95. |
| [16] | Liu, Y., Zhu, Y., Bai, L., Chen, F., Wang, J. and Guo, Y. (2020) Adenocarcino-matous-Predominant Subtype Associated with a Better Prognosis in Adenosquamous Lung Carcinoma. BioMed Central Cancer, 20, 520-526.
https://doi.org/10.1186/s12885-020-06972-5 |
| [17] | Li, C. and Lu, H. (2018) Adenosquamous Carcinoma of the Lung. OncoTargets and Therapy, 11, 4829-4835.
https://doi.org/10.2147/OTT.S164574 |
| [18] | Song, Z., Yu, X. and Zhang, Y. (2017) Clinicopathological Characteris-tics and Survival of ALK, ROS1 and RET Rearrangements in Non-Adenocarcinoma Non-Small Cell Lung Cancer Pa-tients. Cancer Biology and Therapy, 18, 883-887.
https://doi.org/10.1080/15384047.2016.1235660 |
| [19] | Cheng, Y., Yang, J., Wang, D. and Yan, D. (2022) ROS1 Fusion Lung Adenosquamous Carcinoma Patient with Short-Term Clinical Benefit after Crizotinib Treatment: A Case Report. Annals of Translational Medicine, 10, 157-162.
https://doi.org/10.21037/atm-21-6754 |
| [20] | 李廷, 赵丽萍, 胡佳楠, 虞伟妃, 周珏伊, 蓝燕丽, 符丹丽. 肺腺鳞癌伴脑转移患者的预后分析[J]. 浙江医学, 2019, 41(16): 1768-1771. |
| [21] | Hlaing, A.M., Furusato, B., Udo, E., Kitamura, Y., Souda, M., Masutani, M. and Fukuoka, J. (2018) Expression of Phosphatase and Tensin Homolog and Programmed Cell Death Ligand 1 in Adenosquamous Carcinoma of the Lung. Biochemical and Biophysical Research Communications, 503, 2764-2769. https://doi.org/10.1016/j.bbrc.2018.08.037 |
| [22] | Kojima, K., Sakamoto, T., Ka-sai, T., Atagi, S. and Yoon, H. (2022) A Quantitative Evaluation of the Histological Type Dependence of the Pro-grammed Death-Ligand 1 Expression in Non-Small Cell Lung Cancer Including Various Adenocarcinoma Subtypes: A Cross-Sectional Study. Japanese Journal of Clinical Oncology, 52, 281-285.
https://doi.org/10.1093/jjco/hyab202 |
| [23] | Zito Marino, F., Rossi, G., Montella, M., Botti, G., De Cecio, R., Mo-rabito, A., La Manna, C., Ronchi, A., Micheli, M., Salatiello, G., Micheli, P., Rocco, D., Accardo, M. and Franco, R. (2020) Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas. Ameri-can Journal of Surgical Pathology, 44, 378-386.
https://doi.org/10.1097/PAS.0000000000001400 |
| [24] | Liu, Y., Dong, Z., Jiang, T., Hou, L., Wu, F., Gao, G., He, Y., Zhao, J., Li, X., Zhao, C., Zhang, W., Tian, Q., Pan, Y., Wang, Y., Yang, S., Wu, C., Ren, S., Zhou, C., Zhang, J. and Hirsch, FR. (2018) Heterogeneity of PD-L1 Expression Among the Different Histological Components and Meta-static Lymph Nodes in Patients with Resected Lung Adenosquamous Carcinoma. Clinical Lung Cancer, 19, e421-e430. https://doi.org/10.1016/j.cllc.2018.02.008 |
| [25] | Shi, X., Wu, S., Sun, J., Liu, Y., Zeng, X. and Liang, Z. (2017) PD-L1 Expression in Lung Adenosquamous Carcinomas Compared with the More Common Variants of Non-Small Cell Lung Cancer. Scientific Reports, 7, 46209-46215.
https://doi.org/10.1038/srep46209 |
| [26] | Hu, M., Zhang, B., Xu, J., Wang, S., Zhao, Y., Zhang, L. and Han, B. (2019) Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma. Molecular Diagnosis and Therapy, 23, 773-779. https://doi.org/10.1007/s40291-019-00425-x |
| [27] | Cheng, Y., Zhang, Y., Yuan, Y., Wang, J., Liu, K., Yu, B., Xie, L., Ou-Yang, C., Wu, L. and Ye, X. (2021) The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma. Frontiers in Genetics, 11, Article 609405. https://doi.org/10.3389/fgene.2020.609405 |
| [28] | Liu, Q., Wu, L. and Zhang, S. (2021) Transformation of Advanced Lung Adenocarcinoma to Acquired T790M Resistance Mutation Adenosquamous Carcinoma Following Tyrosine Kinase Inhibitor: A Case Report. Tumori Journal, 107, NP5-NP10. https://doi.org/10.1177/0300891620973262 |
| [29] | Zhang, C., Yang, H., Lang, B., Yu, X., Xiao, P., Zhang, D., Fan, L. and Zhang, X. (2018) Surgical Significance and Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase In-hibitors in Patients with Primary Lung Adenosquamous Carcinoma. Cancer Management and Research, 10, 2401-2407. https://doi.org/10.2147/CMAR.S165660 |
| [30] | Lin, G., Li, C., Li, P.S., Fang, W.Z., Xu, H.P., Gong, Y.H., Zhu, Z.F., Hu, Y., Liang, W.H. and Chu, Q. (2020) Genomic Origin and EGFR-TKI Treatments of Pulmonary Adenosqua-mouscarcinoma. Annals of Oncology, 31, 517-524.
https://doi.org/10.1016/j.annonc.2020.01.014 |
| [31] | 任昱恺, 林宗祥, 韦柏充, 杨洋. 基于SEER数据库肺腺鳞癌淋巴结转移预测模型的构建[J]. 河南医学研究, 2022, 31(7): 1198-1203. |
| [32] | 李敏, 许伟, 陈艳, 吴双双, 吴剑卿. 高龄肺腺鳞癌患者免疫治疗一例并文献复习[J]. 中华老年医学杂志, 2020, 39(6): 689-692. |
| [33] | Ma, W., Duan, H., Zhang, R., Wang, X., Xu, H., Zhou, Q. and Zhang, L. (2019) High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome. Journal of Cancer, 10, 267-276. https://doi.org/10.7150/jca.27507 |
| [34] | Zhu, Q., Luo, R., Gu, J., Hou, Y., Chen, Z., Xu, F., Wang, L., Mao, W., Lu, C. and Ge, D. (2020) High CXCR4 Expression Predicts a Poor Prognosis in Resected Lung Adenosqua-mous Carcinoma. Journal of Cancer, 11, 810-818.
https://doi.org/10.7150/jca.36498 |
| [35] | Wang, Y., Qian, F., Hu, M., Chen, Y., Yang, Z. and Han, B. (2021) Clinical Significance of Visceral Pleural and Lymphovascular Invasion in Surgically Resected Adenosquamous Lung Cancer. European Journal of Cardio-Thoracic Surgery, 59, 617-623. https://doi.org/10.1093/ejcts/ezaa353 |
